SiTec Consulting was established in 1996 on the basis of a long industrial experience in Pharmaceutical R&D. We developed a wide range of expertise working with pharmaceutical and biotech companies in the US and Europe. SiTec offers expertise in key areas of Pharmaceutical R&D, from lead/drug candidate selection to Phase I/IIa, for the development of small organic molecules, peptides and proteins; more specifically:
Through the company’s network of laboratories and qualified experts, SiTec has access to state-of-the-art resources at selected specialized companies and research centers , covering fine analytical and formulation technologies, safety and toxicology programs, pre-clinical and early-stage clinical programs. To expand our offer in the areas of formulation and product development, we established a cooperation agreement with Messer Group, in-licensing a novel cryo-spraying process (Variosol®) for its pharmaceutical applications. The technology is based on the use of CO2 in the near or supercritical conditions, and can be applied to the development of micronized formulations and microspheres, in mild conditions and without the use of organic solvents. With Variosol®, SiTec aims to offer to companies in the pharmaceutical and biotech sectors drug products with improved biopharmaceutical and physical-chemical properties, or drug delivery systems with controlled release characteristics.
- Pre-formulation and biopharmaceutical characterization of drugs;
- Formulation and product development, drug delivery;
- Analytical methods development and validation;
- cGLP/cGMP compliance;
- Pharmaceutical and delivery technologies evaluation and assessment;
- Revision of CMC part of dossier for small molecules and biologicals
- Technical training.
Recently, SiTec started a new investigational program on novel delivery systems for Gold Nanorods (GNR) targeting, in collaboration with experts in the field of nanodiagnostics and nanotherapeutics. The program aims to identify and develop novel, targeted-GNR derivatives, for the detection and treatment of specific pathologies with specific unmet needs, eventually reaching initial proof of concept at pre-clinical level.
||Pharmaceutical, biotechnology, product development, biopharmaceutics, Supercritical CO2 technologies, drug delivery, microparticles, gold nanorods, nanoparticles targeting.